[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1450856T3 - Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse - Google Patents

Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse

Info

Publication number
DK1450856T3
DK1450856T3 DK02777600.4T DK02777600T DK1450856T3 DK 1450856 T3 DK1450856 T3 DK 1450856T3 DK 02777600 T DK02777600 T DK 02777600T DK 1450856 T3 DK1450856 T3 DK 1450856T3
Authority
DK
Denmark
Prior art keywords
vlps
cpg
antigens
virus
particles
Prior art date
Application number
DK02777600.4T
Other languages
English (en)
Inventor
Alain Tissot
Katrin Schwarz
Edwin Meijerink
Gerd Lipowsky
Martin F Bachmann
Tazio Storni
Paul Pumpens
Indulis Cielens
Regina Renhofa
Patrik Maurer
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Application granted granted Critical
Publication of DK1450856T3 publication Critical patent/DK1450856T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
DK02777600.4T 2001-09-14 2002-09-16 Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse DK1450856T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31899401P 2001-09-14 2001-09-14
US37414502P 2002-04-22 2002-04-22
PCT/IB2002/004132 WO2003024481A2 (en) 2001-09-14 2002-09-16 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use

Publications (1)

Publication Number Publication Date
DK1450856T3 true DK1450856T3 (da) 2010-05-31

Family

ID=26981773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777600.4T DK1450856T3 (da) 2001-09-14 2002-09-16 Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse

Country Status (13)

Country Link
US (3) US20030099668A1 (da)
EP (2) EP2196217A1 (da)
JP (2) JP4516748B2 (da)
CN (1) CN1599623B (da)
AT (1) ATE447967T1 (da)
AU (2) AU2002339224B2 (da)
CA (1) CA2492826C (da)
CY (1) CY1110585T1 (da)
DE (1) DE60234375D1 (da)
DK (1) DK1450856T3 (da)
ES (1) ES2335979T3 (da)
HK (1) HK1067058A1 (da)
WO (1) WO2003024481A2 (da)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2492823A1 (en) * 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US7682618B2 (en) * 2001-11-07 2010-03-23 The United States Of America As Represented By The Secretary Of The Army Generation of virus-like particles and use as panfilovirus vaccine
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2003089642A1 (en) 2002-04-22 2003-10-30 Bioniche Life Sciences Inc. Oligonucleotide compositions and their use for the modulation of immune responses
CA2486118A1 (en) * 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
AU2003242742B2 (en) * 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
EP1534344A4 (en) * 2002-06-26 2008-05-28 Advanced Bionutrition Corp VIRUSES AND VIRUSIC PARTICLES FOR MULTIPLE ANTIGEN AND TARGET DISPLAY
MXPA05000277A (es) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Configuraciones de antigenos moleculares de usan una particula tipo virus derivada de la proteina de recurimiento ap205.
CA2489008A1 (en) * 2002-07-19 2004-01-29 Cytos Biotechnology Ag Ghrelin-carrier conjugates
RU2450827C2 (ru) * 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6
CA2497798A1 (en) * 2002-09-03 2004-04-22 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
WO2004030631A2 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ZA200507063B (en) 2003-03-26 2007-03-28 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7790189B2 (en) * 2003-05-15 2010-09-07 Mitsui Sugar Co., Ltd. Immunostimulating agents
EP1623229A2 (en) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
JP2009513532A (ja) * 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子
CA2544240A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
WO2005011571A2 (en) * 2003-07-30 2005-02-10 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1961426T1 (sl) 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
KR20060114340A (ko) * 2003-12-01 2006-11-06 다우 글로벌 테크놀로지스 인크. 슈도모나드에서의 재조합 20면체 바이러스-유사 입자 생성
CA2553594A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
PT1740217E (pt) 2004-04-30 2011-08-02 Novartis Ag Vacinação meningocócica conjugada
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2575997A1 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
US20060165723A1 (en) * 2004-09-03 2006-07-27 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
US20080292652A1 (en) * 2004-09-21 2008-11-27 Cytos Biotechnology Ag Virus-Like Particles Comprising a Fusion Protein of the Coat Protein of Ap205 and an Antigenic Polypeptide
CA2588274A1 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
RU2417793C2 (ru) * 2004-10-05 2011-05-10 Цитос Биотехнологи Аг Конъюгаты впч-антиген и их применение в качестве вакцин
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
NZ555590A (en) * 2004-12-13 2009-07-31 Cytos Biotechnology Ag Compositions comprising a VLP and IL-15 protein
US8420102B2 (en) * 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
WO2006083706A2 (en) * 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
AU2006216844B2 (en) 2005-02-18 2012-11-08 Novartis Vaccines And Diagnostics S.R.L. Immunogens from uropathogenic escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
RU2414239C2 (ru) 2005-03-18 2011-03-20 Цитос Биотехнологи Аг Белки, слитые с кошачьим аллергеном, и их применение
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
JP5312028B2 (ja) 2005-09-28 2013-10-09 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
CN101573141B (zh) 2006-05-15 2016-05-04 麻省理工学院 用于功能性颗粒的聚合物
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
AU2013204383B2 (en) * 2006-06-12 2016-09-22 Kuros Us Llc Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
US8586728B2 (en) 2006-12-12 2013-11-19 Cytos Biotechnology Ag Oligonucleotides containing high concentrations of guanine monomers
WO2008071774A1 (en) * 2006-12-14 2008-06-19 Cytos Biotechnology Ag Purification process for coat protein of rna bacteriophages
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) * 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
JP2010524508A (ja) * 2007-04-27 2010-07-22 ダウ グローバル テクノロジーズ インコーポレイティド 可溶性組換え二十面体ウイルス様粒子の生産及びインビボ組織化の改善
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009060440A1 (en) * 2007-11-05 2009-05-14 Mor Research Applications Ltd. Anti-measles cancer immunotherapy
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CN101559224B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脊髓灰质炎疫苗
NO339169B1 (no) * 2008-04-24 2016-11-14 Chemoforma Ltd Funksjonelt fiskefôr omfattende peptidoglykan og nukleotider
GB0808780D0 (en) * 2008-05-15 2008-06-18 Big Dna Ltd Fish vaccines
CN104001169B (zh) 2008-06-27 2016-03-23 硕腾有限责任公司 新颖的佐剂组合物
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
DK2759306T3 (da) * 2008-12-09 2016-05-09 Coley Pharm Group Inc Immunstimulerende oligonukleotider
MX2011006077A (es) 2008-12-09 2011-09-01 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
KR20120034612A (ko) 2009-04-14 2012-04-12 노파르티스 아게 황색 포도상구균에 대한 면역화를 위한 조성물
WO2010122164A1 (en) 2009-04-23 2010-10-28 Cytos Biotechnology Ag VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5
SG175382A1 (en) * 2009-04-30 2011-12-29 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
NZ599059A (en) 2009-09-03 2014-05-30 Pfizer Vaccines Llc Pcsk9 vaccine
MX338753B (es) 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
TWI378144B (en) * 2010-02-09 2012-12-01 Univ Nat Pingtung Sci & Tech Recombinant plasmic containing multicopy cpg motifs and transformant thereof for applying on dna adjuvant in avian vaccines
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2011113546A1 (en) * 2010-03-16 2011-09-22 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2796314A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP3760227A1 (en) * 2011-02-11 2021-01-06 The Trustees of the University of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
CN103747799A (zh) 2011-05-13 2014-04-23 Lsip基金运营联合公司 细胞毒性t细胞诱导剂
EP2714908B1 (en) 2011-05-26 2018-04-18 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
JP6030650B2 (ja) * 2011-07-18 2016-11-24 アメリカ合衆国 ポリオーマウイルス関連病態を阻害するための方法および組成物
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP2014531442A (ja) 2011-09-14 2014-11-27 ノバルティス アーゲー Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉワクチンの組み合わせ
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
AU2012358267B2 (en) 2011-12-21 2017-10-26 Rnaissance Ag Llc Processes using VLPs with capsids resistant to hydrolases
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US20150273042A1 (en) 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions
AU2013240248B2 (en) 2012-03-26 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of packaged RNA to mammalian cells
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
BR112014026812A8 (pt) 2012-04-26 2022-10-04 Novartis Ag Antígenos e combinações de antígenos
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたｂ型肝炎コアポリペプチド
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
RU2717306C2 (ru) 2013-03-15 2020-03-19 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
WO2014145932A2 (en) * 2013-03-15 2014-09-18 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
SG10201805197VA (en) 2013-06-19 2018-07-30 Apse Llc Compositions and methods using capsids resistant to hydrolases
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015024992A2 (en) * 2013-08-22 2015-02-26 Cytos Biotechnology Ag Treatment of asthma
RU2730011C2 (ru) 2013-09-19 2020-08-14 Зоэтис Сервисиз Ллс Адъюванты на масляной основе
JP6861516B2 (ja) 2013-12-16 2021-04-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｌｐ−レプリコンを用いたクラスｉｉ ｍｈｃ抗原の送達による癌免疫療法
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
KR102290205B1 (ko) 2014-06-04 2021-08-20 엑시큐어, 인크. 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
NZ771297A (en) * 2014-12-31 2024-11-29 Checkmate Pharmaceuticals Inc Combination tumor immunotherapy
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US11058760B2 (en) 2016-04-18 2021-07-13 University Of Florida Research Foundation, Incorporated N-antigenic form poliovirus virus-like particles comprising thermostable mutations
NZ747512A (en) 2016-04-27 2023-05-26 Benchmark Animal Health Ltd Treatment of canine atopic dermatitis
EP3448418A1 (en) 2016-04-27 2019-03-06 Allergy Therapeutics (UK) Limited Treatment of peanut allergy
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
US10434171B2 (en) 2016-12-23 2019-10-08 United States of America as Represented by Secretary of Agriculture Microfluidized Mycobacterium avium fragments as an adjuvant and carrier for mucosal vaccine delivery
US10566881B2 (en) 2017-01-27 2020-02-18 Franklin Electric Co., Inc. Motor drive system including removable bypass circuit and/or cooling features
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
US12084655B2 (en) 2018-04-09 2024-09-10 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
CN112105733B (zh) 2018-04-19 2024-10-29 查美特制药公司 合成rig-i样受体激动剂
EP3835414A4 (en) * 2018-08-07 2022-05-25 Institute Of Biophysics, Chinese Academy Of Sciences CD4+ T LYMPHOCYTE ACTIVATION METHOD
JP7623282B2 (ja) 2018-12-20 2025-01-28 サイバ アクチェンゲゼルシャフト 融合によって修飾されたｃｍｖのウイルス様粒子
CA3138008A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12161710B2 (en) 2019-07-24 2024-12-10 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2021081353A1 (en) 2019-10-23 2021-04-29 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
CN111166727A (zh) * 2019-11-15 2020-05-19 河南省生物工程技术研究中心 一种肿瘤免疫治疗复合物及其制备方法和用途
CN110862435B (zh) * 2019-12-05 2021-09-24 中国农业大学 非洲猪瘟ctl表位多肽及其应用
CN111214663B (zh) * 2020-03-06 2022-03-15 中国人民解放军军事科学院军事医学研究院 Tmed2在作为埃博拉病毒病治疗靶点中的应用
CN111253494B (zh) * 2020-03-10 2022-04-26 天康制药(苏州)有限公司 猪口蹄疫病毒和猪轮状病毒的融合蛋白、类病毒颗粒和疫苗及制备方法
CN111281973A (zh) * 2020-03-31 2020-06-16 清华大学 含有trpv2激动剂的疫苗佐剂及其用途
CU20200028A7 (es) * 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
WO2021252450A1 (en) * 2020-06-08 2021-12-16 Adaptive Phage Therapeutics, Inc. Phage display vaccine for covid-19 using a novel peptide sequence
CA3185429A1 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
WO2021260131A1 (en) 2020-06-25 2021-12-30 Saiba AG Virus-like particles of cmv modified by fusion
CN113136372B (zh) * 2021-05-28 2023-08-01 广西大学 一种重组噬菌体的构建方法
US12121574B2 (en) * 2021-09-28 2024-10-22 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2024047090A2 (en) 2022-08-30 2024-03-07 Saiba Animal Health Ag Modified virus-like particles of cmv
WO2024049946A1 (en) 2022-08-31 2024-03-07 Unm Rainforest Innovations Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (asc) and methods of use
WO2024081953A2 (en) * 2022-10-14 2024-04-18 Longhorn Vaccines And Diagnostics, Llc Vaccines and antibodies for the treatment and prevention of microbial infections
WO2024091589A1 (en) * 2022-10-28 2024-05-02 Unm Rainforest Innovations Malaria immunogen and methods for using same
WO2024164006A2 (en) * 2023-02-03 2024-08-08 The Regents Of The University Of California Self-amplifying rna form of a constitutively-active sting protein for enhancing t-cell response to antigenpresenting cells

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2034118A1 (en) 1970-07-09 1972-01-13 Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
FR2581394B1 (fr) 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
CA2140542A1 (en) 1992-07-27 1994-02-03 Abeysingle Padmapriya Oligonucleotide alkylphosphonothioates
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
DK0732936T3 (da) 1993-12-09 2000-09-04 Heinrich Exner Adjuvans til antigener, fremgangsmåde til fremstilling og anvendelse
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP1167377B2 (en) * 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US5994315A (en) 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
ZA9756B (en) 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
CA2246162C (en) 1996-01-23 2000-04-04 Icn Pharmaceuticals, Inc. Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes
WO1997028259A1 (en) 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
CA2288129A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DE69840850D1 (de) 1997-06-06 2009-07-09 Dynavax Tech Corp Inhibitoren von immunstimulatorischen dna sequenz aktivität
WO1998058951A1 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
AU745951B2 (en) 1997-08-05 2002-04-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New immunoprotective influenza antigen and its use in vaccination
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
ATE353657T1 (de) 1997-09-05 2007-03-15 Univ California Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
IL137766A0 (en) 1998-02-12 2001-10-31 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6541438B1 (en) * 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
NZ508650A (en) * 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
KR100766016B1 (ko) 1998-06-30 2007-10-11 옴 파르마 아실 유사디펩티드, 이의 제조 방법 및 이를 함유하는 약제 조성물
CA2333854A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
AU5254799A (en) 1998-08-04 2000-02-28 Dryken Technologies, Inc. Method and system for dynamic data-mining and on-line communication of customized information
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
US5962636A (en) * 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
EP1108017A2 (en) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH G-motif oligonucleotides and uses thereof
ES2258869T3 (es) * 1998-10-21 2006-09-01 The United States Government As Represented By The Department Of Health And Human Services Particulas similares a virus para la induccion de autoanticuerpos.
AU768807B2 (en) * 1998-11-30 2004-01-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
CA2357004A1 (en) 1998-12-23 2000-06-29 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis b surface antigens in transgenic plants
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2003520568A (ja) * 1999-02-02 2003-07-08 バイオカシェ ファーマシューティカルズ， インコーポレイテッド 高度な抗原提示プラットフォーム
JP2002535994A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 標的ｄｎａのインビボ除去による遺伝子修復
HUP0105490A3 (en) 1999-02-25 2002-05-28 Peptide Therapeutics Ltd Cambr Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
US8206749B1 (en) * 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
ES2250151T3 (es) 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
AU774380B2 (en) 1999-08-19 2004-06-24 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
AU6801800A (en) 1999-08-30 2001-03-26 Ludwig Institute For Cancer Research Isolated nona and decapeptides which bind to hla molecules, and the use thereof
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001022990A2 (en) 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
PT1221968E (pt) * 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001038358A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Hbv/hcv virus-like particle
CA2397374A1 (en) 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
US6261326B1 (en) 2000-01-13 2001-07-17 North Carolina State University Method for introducing dyes and other chemicals into a textile treatment system
WO2001095935A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
EP1261366A4 (en) * 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
WO2001077158A1 (en) 2000-04-07 2001-10-18 University Of Leeds Innovations Limited Hepatitis b core antigen fusion proteins
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
WO2001098333A2 (en) 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
JP2004511527A (ja) 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2003040308A2 (en) 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
CA2457804C (en) 2001-08-13 2012-10-16 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
ES2335979T3 (es) * 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
CA2492823A1 (en) * 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ES2321491T3 (es) 2001-10-05 2009-06-08 Cytos Biotechnology Ag Conjugados que llevan peptido angiotensina y uso de los mismos.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
WO2003030656A2 (en) 2001-10-06 2003-04-17 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
ATE419007T1 (de) 2001-11-07 2009-01-15 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
IL161146A0 (en) 2001-11-07 2004-08-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AU2002354191A1 (en) 2001-12-04 2003-06-17 Atock Co., Ltd. Quartz glass single hole nozzle and quartz glass multi-hole burner head for feeding fluid
AU2003205623A1 (en) 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
AU2003242742B2 (en) * 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
MXPA05000277A (es) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Configuraciones de antigenos moleculares de usan una particula tipo virus derivada de la proteina de recurimiento ap205.
RU2450827C2 (ru) 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6
ZA200507063B (en) * 2003-03-26 2007-03-28 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
JP2009513532A (ja) * 2003-07-10 2009-04-02 サイトス バイオテクノロジー アーゲー パッケージ化ウイルス様粒子
US20080292652A1 (en) * 2004-09-21 2008-11-27 Cytos Biotechnology Ag Virus-Like Particles Comprising a Fusion Protein of the Coat Protein of Ap205 and an Antigenic Polypeptide
CA2588274A1 (en) 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
RU2414239C2 (ru) 2005-03-18 2011-03-20 Цитос Биотехнологи Аг Белки, слитые с кошачьим аллергеном, и их применение
JP5312028B2 (ja) 2005-09-28 2013-10-09 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用
WO2007068747A1 (en) * 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CN101951943A (zh) 2007-12-20 2011-01-19 赛托斯生物技术公司 神经生长因子偶联物及其用途
US20110262472A1 (en) 2008-04-22 2011-10-27 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof

Also Published As

Publication number Publication date
AU2009200115A1 (en) 2009-02-05
CA2492826A1 (en) 2003-03-27
US20030099668A1 (en) 2003-05-29
JP4749475B2 (ja) 2011-08-17
DE60234375D1 (de) 2009-12-24
HK1067058A1 (en) 2005-04-01
CA2492826C (en) 2016-12-13
ES2335979T3 (es) 2010-04-07
US20120301499A1 (en) 2012-11-29
CN1599623A (zh) 2005-03-23
US20150030620A1 (en) 2015-01-29
ATE447967T1 (de) 2009-11-15
JP4516748B2 (ja) 2010-08-04
WO2003024481A2 (en) 2003-03-27
EP2196217A1 (en) 2010-06-16
AU2002339224B2 (en) 2008-10-09
US9950055B2 (en) 2018-04-24
CN1599623B (zh) 2011-05-11
WO2003024481A3 (en) 2004-06-03
CY1110585T1 (el) 2015-04-29
US8691209B2 (en) 2014-04-08
AU2009200115B2 (en) 2012-05-03
EP1450856A2 (en) 2004-09-01
JP2005517632A (ja) 2005-06-16
EP1450856B1 (en) 2009-11-11
JP2009197001A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
DK1450856T3 (da) Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
WO2004084939A3 (en) Hiv-peptide-carrier-conjugates
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
WO2002034205A3 (en) Using heat shock proteins to increase immune response
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
NO20050396L (no) Adjuvant viral partikkel
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
WO2007066188A3 (en) Marked bovine viral diarrhea virus vaccines
WO2003031569A3 (en) Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
EP1593738A4 (en) VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
WO2003025002A3 (en) Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
WO2003094829A3 (en) Pathogen vaccines and methods for using the same
Paoletti Recombinant avipox virus
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
WO2007050102A3 (en) Dendritic cell based vaccines